Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case series

Blood Cancer J. 2022 Jan 25;12(1):11. doi: 10.1038/s41408-022-00607-7.

Authors

Jennifer L Oliveira¹, Patricia T Greipp², Aruna Rangan¹, Aminah Jatoi³, Phuong L Nguyen¹

Affiliations

¹ Division of Hematopathology, Mayo Clinic, Rochester, MN, USA.
² Division of Laboratory Genetics and Genomics, Mayo Clinic, Rochester, MN, USA.
³ Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA. jatoi.aminah@mayo.edu.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Bone Marrow / pathology
Cytogenetic Analysis
Female
Humans
Leukemia, Myeloid, Acute / chemically induced*
Leukemia, Myeloid, Acute / genetics
Leukemia, Myeloid, Acute / pathology
Middle Aged
Myelodysplastic Syndromes / chemically induced*
Myelodysplastic Syndromes / genetics
Myelodysplastic Syndromes / pathology
Neoplasms / drug therapy
Poly(ADP-ribose) Polymerase Inhibitors / adverse effects*
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use

Substances

Poly(ADP-ribose) Polymerase Inhibitors